<DOC>
	<DOCNO>NCT01618890</DOCNO>
	<brief_summary>Study hypothesis : Hepatic venous pressure gradient ( HVPG ) -directed primary prophylaxis nonselective beta-blocker therapy ( NSBB ) lead reduction first variceal bleed episode cost-effective long term . Study design : A multi-center randomized control study compare nonselective beta-blocker therapy guide hemodynamic response determine difference HVPG start oral NSBB therapy , standard heart rate-guided NSBB therapy patient esophageal varix due liver cirrhosis without history esophageal variceal hemorrhage . Primary study parameters/outcome study : First variceal bleed episode occur within first two year . Secondary study parameters/outcome study : - Mortality - Occurrence cirrhosis-related complication - Occurrence hepatocellular carcinoma - Costs treatment - Adverse effect</brief_summary>
	<brief_title>Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy Primary Prevention Variceal Bleeding</brief_title>
	<detailed_description>Background study : About 50 % cirrhotic patient use nonselective beta-blockers ( NSBB ) primary prevention variceal bleed reach target hemodynamic response , define HVPG &lt; 12 mmHg &gt; 20 % decrease HVPG baseline . These so-called hemodynamic nonresponding patient significantly high rate first esophageal variceal hemorrhage compare patient respond NSBB . International institution publish guideline differ recommendation concern HVPG monitoring . As result , practice currently vary widely . The investigator hypothesize HVPG-directed primary prophylaxis lead reduction first variceal bleed episode cost-effective long term . Objective study : To determine cost-effectiveness hepatic venous pressure gradient ( HVPG ) -guided nonselective beta-blocker therapy compare standard heart rate-guided beta-blocker therapy primary prevention esophageal variceal bleed cirrhotic patient . Study design : A multi-center randomized control study compare nonselective beta-blocker therapy guide hemodynamic response determine difference HVPG start oral nonselective beta-blockers , standard heart rate-guided nonselective beta-blocker therapy patient esophageal varix due liver cirrhosis . Study population : Patients liver cirrhosis large ( &gt; 5 mm ) esophageal varix without history esophageal variceal hemorrhage . Intervention : -In HVPG-group : Perform baseline HVPG measurement , start propranolol 20 mg orally twice daily ( BID ) , increase dose stepwise 3 day interval decrease heart rate maximum tolerate dose . After 4 week second HVPG perform . In hemodynamic responder ( reach target decrease HVPG ) NSBB continue end follow-up . In hemodynamic nonresponders ( reach target decrease HVPG ) , NSBB continue repeat endoscopic band ligation perform 2-4 week interval complete obliteration large varix . -In control group : Start propranolol 20 mg BID , increase dose stepwise 3 day interval maximum heart rate-guided tolerate dose . Primary study parameters/outcome study : First variceal bleed episode occur within first two year . Secondary study parameters/outcome study : Mortality Occurrence cirrhosis-related complication Occurrence hepatocellular carcinoma Costs treatment Adverse effect</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Patients liver cirrhosis Large ( â‰¥5 mm ) esophageal varix History esophageal variceal hemorrhage Pregnancy Contraindications betablocker therapy Esophageal varix absence liver cirrhosis Intermediate , advance terminal stage hepatocellular carcinoma ( BCLC stage B , C D ) Refractory ascites Hepatorenal syndrome Prior treatment prophylaxis esophageal varix varix bleed ( propranolol use , TIPS , endoscopic band ligation , endoscopic sclerotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Esophageal variceal bleeding</keyword>
	<keyword>Hepatic Venous Pressure Gradient</keyword>
	<keyword>Betablocker therapy</keyword>
</DOC>